Л Б Полушкина
Russian Research Institute of Hematology and Transfusiology · 69 works · 47 citations · h-index 4
Top works
- The combination treatment regimen of ruxolitinib with low‐dose mercaptopurine or cytarabine in frail patients with blast‐phase myelofibrosis
- It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics
- Early Molecular Response in Chronic Myeloid Leukemia Patients Predicts Future Response Status
- Genetic Markers of Hereditary Thrombophilia and Risk of Thrombotic Complications in Patients with Polycythemia Vera
- Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience
- Targeted Therapy of Myelofibrosis
- Morphological Differential Diagnosis of Primary Myelofibrosis and Essential Thrombocythemia with Computer Cluster Analysis of a Megakaryocytic Lineage in Myeloid Tissue
- Role of FLT3 gene mutations in acute myeloid leukemia: effect on course of disease and results of therapy
- Analysis haemostatic system gene polymorphism in pregnant women without complications from Russia and Ukraine
- Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment
- The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement
- Prognostic Value of Genetic Mutations in Patients with Acute Myeloid Leukemias: Results of a Cooperative Study of Hematology Clinics of Saint Petersburg (Russia) and Charite Clinic (Germany)
- Atypical Chronic Myeloid Leukemia Challenge in Russian Hematology Practice
- Current Genetic Models for Prediction of Primary Myelofibrosis
- PB2232 THE NATURAL ANTICOAGULANTS IN PATIENTS WITH PHILADELPHIA‐NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
- Molecular Genetic Markers and Clinical Characteristics of Essential Thrombocythemia
- Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
- THROMBOTIC AND BLEEDING RISK FACTORS IN ESSENTIAL THROMBOCYTHEMIA
- PB2197 NEXT-GENERATION SEQUENCING IN CLINICAL PRACTICE: MOLECULAR EVENTS AND COURSE OF MYELOPROLIFERATIVE NEOPLASMS
- Прогноз выживаемости и результаты таргетной терапии хронического миелолейкоза